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Introduction
Breast pathologists have for many years been seeking to
demonstrate a sequence of morphologically distinguish-
able cellular changes that define a linear sequence of
transformation of normal breast ductal epithelium to the
fully malignant state. It is still not entirely clear that this has
been achieved, but a general model consists of premalig-
nant changes (a variety of hyperplasias) followed by DCIS
with subsequent invasive disease [1,2]. There are alterna-
tive views that these changes are neither linear nor do
they always entail each intermediate phenotype [3]. Clini-
cally, however, there are clear distinctions between these
stages in terms of the risk to the patient, which affects the
choice of treatment.
It has been hoped that the description of the underlying
molecular changes accompanying these morphologically
defined stages, and at least a partial understanding of
their significance, would enable pathologists to confirm or
refute their models and to allow individual cases to be
placed in the sequence. This has to some extent been
achieved; many molecular changes at the level of the DNA
have been found in DCIS but not in premalignant disease.
Somewhat disappointingly, however, little if anything is
known definitively about any additional molecular changes
that are presumed to result in the transition from DCIS to
invasive disease. Research continues into this problem
using methods that minimise preconceptions such as
genomic analysis and gene expression analysis.
The molecular changes seen in DCIS include mutations in
the p53 gene [4], and gene amplification and overexpres-
sion at the protein level of the c-erbB-2 receptor tyrosine
kinase [5]. There is a higher prevalence of both these events
in more undifferentiated DCIS (known as comedo cancer in
previous terminologies) [6], suggesting a functional signifi-
cance, but this had not been definitively established.
Growth factor receptor activation leads to a
DCIS-like phenotype
The hypothesis that growth factor receptor activation
leads to a DCIS-like phenotype is tested in an article by
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Muthuswamy  et al. [7]. Two groups cooperated in that
work, each bringing a different technological contribution.
Mina Bissell, the doyen of breast cancer cell biologists,
developed three-dimensional cell culture models of normal
breast epithelial cells over several years [8]. Joan Brugge
explored the mechanisms of growth factor receptor sig-
nalling and developed a system in which ectopically
expressed receptors can be selectively activated at will by
the addition of drugs [9].
The c-erbB-2 protein, which is overexpressed in DCIS, is a
member of the epidermal growth factor receptor (EGFR)
family. This family consists of the EGFR, c-erbB-2 and two
more receptors (c-erbB-3 and c-erbB-4) [10,11]. Each
protein has an extracellular domain, which in some cases
recognises an activating ligand, a transmembrane domain
and a cytoplasmic domain with protein tyrosine kinase
enzyme activity. Ligand binding induces receptor dimerisa-
tion, activation of the kinase and phosphorylation of tyrosine
residues in the cytoplasmic domain. The phosphorylated
protein then recruits and activates a variety of intracellular
second messenger systems that induce changes to the
cytoskeleton and that can stimulate the rate of cell division.
Brugge and colleagues [9] have constructed altered
receptors in which the extracellular domain is derived from
the nerve growth factor receptor and cytoplasmic domains
from either the EGFR or the c-erbB-2 receptor. In addition,
however, there is a sequence fused to the C-termini of the
constructs derived from the FK506-binding protein. The
membrane-permeable bivalent compound AP1510 binds
to this region and induces dimerisation, phosphorylation
and intracellular signal transduction, allowing selective,
acute or chronic receptor activation [8].
In the study reported in Nature Cell Biology [7],
Muthuswamy  et al. introduced the chimeric EGFR and
c-erbB-2 separately into MCF10A cells (immortal but
untransformed human mammary epithelial cells) and
established stable lines expressing moderate levels of
either receptor. In the absence of AP1510, these grew in
three-dimensional cultures, indistinguishable from the
untransfected cells, as structures highly reminiscent of
mammary epithelial acini. Each acinar structure contained
approximately 20–40 cells with basally located nuclei and
a lumen. Staining for cell adhesion molecules showed that
the cells were polarised and surrounded by a collagen
layer similar to a basement membrane.
The chimeric EGFR was able to stimulate growth of the
MCF10A cells in monolayer culture, demonstrating that it
was functional, but activation by the addition of AP1510
had no effect on cell behaviour or morphology when the
cells were grown in three-dimensional cultures. Strikingly,
however, activation of the c-erbB-2 protein caused
marked changes in the polarised acinar structures. These
lost their polarised organisation and grew into structures
described as ‘consisting of multiple acinar-like units with
filled lumina’; in some cases, a hundred times the size of
untreated structures. Muthuswamy et al. [7] conclude that
the EGFR and c-erbB-2 ‘have different abilities to affect
polarised and growth arrested acini’ and that ‘acute activa-
tion of c-erbB-2 results in the generation of multi-acinar
structures that share properties with structures associated
with carcinoma in situ’.
Significance of the results for future treatment
DCIS is often treated surgically by mastectomy rather than
breast-conserving surgery since it is commonly multifocal
and sometimes extensive [12–14]. Failure to completely
remove the disease is associated with a low but significant
probability of the subsequent development of invasive
cancer. It would be highly desirable to identify effective,
low-toxicity adjuvant therapy that might justify the use of
more limited surgery.
The formal demonstration by Muthuswamy et al. that over-
expression of c-erbB-2 in normal breast ductal epithelial
cells leads to a DCIS-like phenotype provides strong
support for studying such treatments in more detail in
model systems. In independent work, Bundred and
coworkers [15] have developed a xenograft system in
which small pieces of human DCIS are implanted subcuta-
neously in nude mice where the tissue survives and grows.
Treatment of the mice with herceptin (a monoclonal anti-
body to the human c-erbB-2 protein now used for the
treatment of some invasive breast cancers) did not have
any effect, but treatment with iressa (a small-molecule
tyrosine kinase inhibitor that acts principally on the EGFR
but that will also, at higher concentrations, inhibit c-erbB-2)
did inhibit cancer cell growth. It is also possible that
heterodimers between EGFR and c-erbB-2 are important
in signalling in this context, and that these will also be
inhibited to a degree by the tyrosine kinase inhibitor.
The presented results suggest that antibodies may not be
the first method of choice for treatment of DCIS of the
breast because they are large molecules and may have
limited access to the interior of the cancer-filled duct.
Orally available small-molecule tyrosine kinase inhibitors
are more promising, and several pharmaceutical compa-
nies have selective c-erbB-2/EGFR inhibitors in develop-
ment. Should these studies prove encouraging, there
would be a rationale for testing these inhibitors in cases of
ductal carcinoma of the breast in clinical trials.
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